Lipoprotein(a)

Lipoprotein(a) – Lp(a) – is an hepatically synthesized lipoprotein, structurally similar to low-density-lipoprotein, and an important marker for cardiovascular risk. Lp(a) plasma concentrations are genetically determined and can hardly be modified by diet, exercise or oral drugs. Lp(a) concentration...

Descripción completa

Detalles Bibliográficos
Autores principales: Reuser, Annika, Koenig, Wolfgang, Laufs, Ulrich
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Georg Thieme Verlag KG 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9668486/
https://www.ncbi.nlm.nih.gov/pubmed/36323326
http://dx.doi.org/10.1055/a-1516-2701
_version_ 1784831923995017216
author Reuser, Annika
Koenig, Wolfgang
Laufs, Ulrich
author_facet Reuser, Annika
Koenig, Wolfgang
Laufs, Ulrich
author_sort Reuser, Annika
collection PubMed
description Lipoprotein(a) – Lp(a) – is an hepatically synthesized lipoprotein, structurally similar to low-density-lipoprotein, and an important marker for cardiovascular risk. Lp(a) plasma concentrations are genetically determined and can hardly be modified by diet, exercise or oral drugs. Lp(a) concentration should be tested at least once per life. The current treatment for high Lp(a) is early intensive risk factor management with optimal lowering of LDL-cholesterol. Potent new RNA-targeting therapies are currently assessed in clinical trials and may be available in a couple of years.
format Online
Article
Text
id pubmed-9668486
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Georg Thieme Verlag KG
record_format MEDLINE/PubMed
spelling pubmed-96684862022-11-17 Lipoprotein(a) Reuser, Annika Koenig, Wolfgang Laufs, Ulrich Dtsch Med Wochenschr Lipoprotein(a) – Lp(a) – is an hepatically synthesized lipoprotein, structurally similar to low-density-lipoprotein, and an important marker for cardiovascular risk. Lp(a) plasma concentrations are genetically determined and can hardly be modified by diet, exercise or oral drugs. Lp(a) concentration should be tested at least once per life. The current treatment for high Lp(a) is early intensive risk factor management with optimal lowering of LDL-cholesterol. Potent new RNA-targeting therapies are currently assessed in clinical trials and may be available in a couple of years. Georg Thieme Verlag KG 2022-11-02 /pmc/articles/PMC9668486/ /pubmed/36323326 http://dx.doi.org/10.1055/a-1516-2701 Text en The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/) https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License, which permits unrestricted reproduction and distribution, for non-commercial purposes only; and use and reproduction, but not distribution, of adapted material for non-commercial purposes only, provided the original work is properly cited.
spellingShingle Reuser, Annika
Koenig, Wolfgang
Laufs, Ulrich
Lipoprotein(a)
title Lipoprotein(a)
title_full Lipoprotein(a)
title_fullStr Lipoprotein(a)
title_full_unstemmed Lipoprotein(a)
title_short Lipoprotein(a)
title_sort lipoprotein(a)
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9668486/
https://www.ncbi.nlm.nih.gov/pubmed/36323326
http://dx.doi.org/10.1055/a-1516-2701
work_keys_str_mv AT reuserannika lipoproteina
AT koenigwolfgang lipoproteina
AT laufsulrich lipoproteina

Ejemplares similares